1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.
2. Barzman, D., Delbello, M. P., Kowatch, R. A., Gernert, B., Fleck, D. E., Pathak, S., et al. (2004). The effectiveness and tolerability of Aripiprazole for pediatric bipolar disorders: A retrospective chart review. Journal of Child and Adolescent Psychopharmacology, 14, 593–600.
3. Bastiaens, L., & Bastiaens, D. (2005). Pediatric experience with Aripiprazole. New Research Abstracts, 158th Annual Meeting, A.P.A., p. 157.
4. Bastiaens, L., & Dello Stritto, C. (2004). Validity and reliability of the health and life functioning scale. Scientific Proceedings, 51st Annual Meeting, A.A.C.A.P., p. 108.
5. Biederman, J., Mick, E., Harpold, T., Hammerness, P., Doyle, R., Aleardi, M., et al. (2006). Open-label study of Aripiprazole in youth with bipolar disorder. New Research Abstracts, 159th Annual Meeting, A.P.A., p. 262.